Form 4: Gilead Sciences Executive Johanna Mercier Reports Stock Award Vesting and Share Disposals
SEC Form 4
Chief Commercial Officer Johanna Mercier reports vesting of performance share awards and subsequent disposal of shares to cover tax obligations.
Summary
- Johanna Mercier, Chief Commercial Officer of Gilead Sciences, reported transactions involving the company's common stock on February 4, 2025.
- These transactions include the vesting of performance share awards granted on March 10, 2022, March 10, 2023 and March 10, 2024.
- A total of 19,793 shares from the 2023 and 70,712 shares from the 2022 awards vested after the Compensation and Talent Committee certified the attainment of performance goals.
- Mercier disposed of 45,666 shares at a price of $97.99 to satisfy tax obligations related to the vesting of these awards.
- Following these transactions, Mercier directly owns 119,979 shares of Gilead Sciences common stock and 165,645 shares of Gilead Sciences common stock.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This filing is a routine disclosure of insider transactions and provides insight into executive compensation and ownership at Gilead Sciences. It is typical for executives to receive stock awards as part of their compensation and to sell shares to cover tax obligations upon vesting.
Comparison to Industry Standards
- Stock-based compensation is a common practice among publicly traded companies, particularly in the pharmaceutical and biotechnology industries.
- Companies like Amgen (AMGN), AbbVie (ABBV), and Johnson & Johnson (JNJ) also utilize performance-based equity awards to incentivize their executives.
- The vesting schedules and performance metrics associated with these awards vary depending on the company's specific goals and compensation philosophy.
- Executive stock ownership is generally viewed positively by investors as it aligns management's interests with those of shareholders.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders.
- Shareholders may view the executive's stock ownership as a positive sign of alignment with their interests.
Key Dates
| Date | Description |
|---|---|
| 2022-03-10 | Date of performance share award grant to the Reporting Person. |
| 2023-03-10 | Date of performance share award grant to the Reporting Person. |
| 2024-03-10 | Date of performance share award grant to the Reporting Person. |
| 2025-02-04 | Date of transaction: Vesting of performance share awards and disposal of shares. |
| 2025-02-06 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.